Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients

Ilan Cohen, Eran Perel, Dov Flex, Ron Tepper, Marco M Altaras, Mario Cordoba, Yoram Beyth

Abstract

Aims—To evaluate whether endometrial pathology is more likely to be diagnosed in gynaecologically symptomatic rather than in gynaecologically asymptomatic postmenopausal breast cancer patients with tamoxifen treatment; and to evaluate the possible influence of various clinical factors on the incidence of endometrial pathology.

Methods—Endometrial histological findings, transvaginal ultrasonographic endometrial thickness, demographic characteristics, health habits, and risk factors for endometrial cancer were compared between 14 gynaecologically symptomatic (group I) and 224 gynaecologically asymptomatic (group II) postmenopausal breast cancer patients with tamoxifen treatment.

Results—Overall, 28.6% of the study population had endometrial pathology. The incidence of overall positive endometrial histological findings was significantly higher in group I than in group II (92.9% vs 24.6%, p < 0.0001). Atrophic endometrium was more common in group II than in group I (75.3% vs 7.1%, p < 0.0001). Most other endometrial pathologies was significantly more common in group I than in group II (endometrial hyperplasia, 35.7% vs 5.6%, p < 0.0001; endometrial polyps, 35.7% vs 13.4%, p < 0.0111; endometrial carcinoma, 21.5% vs 0.9%, p < 0.0001). Endometrial pathology appeared considerably later in the gynaecologically asymptomatic patients than in gynaecologically symptomatic patients (p = 0.0002). Vaginal bleeding or spotting occurred exclusively in group I. The incidence of endometrial pathology in the entire study population was consistent with that reported elsewhere, and higher than that reported for healthy postmenopausal women.

Conclusions—Endometrial pathology is more likely to be diagnosed in gynaecologically symptomatic postmenopausal breast cancer patients with tamoxifen treatment, and after a shorter duration of time, than in gynaecologically asymptomatic patients.

Keywords: tamoxifen; endometrial pathology

Tamoxifen is a non-steroidal antioestrogen that is considered to be the antihormonal treatment of choice for advanced breast cancer in postmenopausal patients with positive oestrogen receptor proteins. It is known to be safe, effective, and to have minimal side effects.

Over the past decade, tamoxifen has been reported to be associated with various endometrial pathologies, such as endometrial hyperplasia, endometrial polyps, and endometrial carcinoma.

Many studies have compared the incidence of these endometrial pathologies between tamoxifen treated postmenopausal breast cancer patients and similar untreated patients. Others have compared asymptomatic tamoxifen treated postmenopausal patients and similar untreated patients.

To the best of our knowledge, there have only been three studies that have compared the histological findings in gynaecologically symptomatic and similar gynaecologically asymptomatic postmenopausal tamoxifen treated patients. However, two of these did not show any significant difference in the occurrence of endometrial pathology between the two groups, while the third did show a difference. No studies have examined the different factors that may influence the incidence of endometrial pathology between gynaecologically symptomatic and gynaecologically asymptomatic postmenopausal breast cancer patients on tamoxifen.

In this study we compared endometrial histology and transvaginal ultrasonographic measurement of endometrial thickness, demographic characteristics, health habits, and risk factors for endometrial cancer between gynaecologically symptomatic and gynaecologically asymptomatic postmenopausal breast cancer patients given tamoxifen treatment. This study was designed to evaluate whether endometrial pathology is more likely to develop in gynaecologically symptomatic than in gynaecologically asymptomatic patients, and to evaluate the possible impact of various factors on the incidence of endometrial pathology.

Methods

Since 1 September 1989 all postmenopausal breast cancer patients who were under medical supervision or treatment in our institutions were followed up in the gynaecological outpatient clinic, using an investigative protocol.

Department of Obstetrics and Gynaecology, Sapir Medical Centre, Kfar Saba 44281, Israel
I Cohen
E Perel
R Tepper
Y Beyth

Department of Pathology, Sapir Medical Centre
M Cordoba

Gynaecological Oncology Unit, Sapir Medical Centre
M M Altaras

Department of Oncology, Rabin Medical Centre, Petah Tikva, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Israel
D Flex

Correspondence to:
Dr Ilan Cohen.

Accepted for publication
27 October 1998
None of the women in the study had ever undergone hysterectomy.

Hormone therapy: All patients in this study were treated with 20–30 mg of tamoxifen daily (Abic, Chemical and Pharmaceutical Industries, Netanya, Israel).

None of the women in the study had ever received any postmenopausal oestrogen replacement therapy.

**Results**

Demographic characteristics and health habits are compared between the two study groups in Table 1. A comparison of risk factors for endometrial cancer: age at menarche, age at first delivery, age at menopause, weight, hypertension, diabetes mellitus, serum oestradiol, oestrogen replacement therapy, and various treatments for the primary breast cancer.

When insufficient tissue for histological diagnosis was obtained the finding was classed as negative. A positive histological finding was defined in any case where enough tissue was obtained from endometrial sampling for histological evaluation.

All patients in this study were treated with 20–30 mg of tamoxifen daily (Abic, Chemical and Pharmaceutical Industries, Netanya, Israel).

None of the women in the study had ever received any postmenopausal oestrogen replacement therapy.

**Statistics**

Statistical analysis was performed using the two sample t test, analysis of variance with multiple comparisons, and Fisher’s exact test. The log rank test was used to test the probability of freedom from endometrial pathologies with respect to the length of tamoxifen treatment between the two groups, which is expressed in a Kaplan–Meier curve.

Significant statistical differences were assumed at a p value of < 0.05.

**Results**

Demographic characteristics and health habits are compared between the two study groups in Table 1. A comparison of risk factors for endometrial cancer between the two study groups is given in Table 2. A comparison of risk factors for endometrial cancer in the two study groups is given in Table 3.
transvaginal sonography was greater in group I patients than in group II patients, but this difference was also not significant (mean (SD), 18.35 (17.47) mm vs 13.27 (8.12) mm, NS).

Overall, 68 (28.6%) of the entire study population had endometrial pathology and 170 (71.4%) had either an atrophic endometrium or else insufficient tissue was obtained for histological evaluation on endometrial sampling. Proliferative endometrium was diagnosed in 11 patients (4.6%), endometrial hyperplasia in 17 (7.1%), endometrial polyps in 35 (14.7%), and endometrial carcinoma in five (2.1%). A comparison of endometrial histological findings detected in the two groups is given in table 4.

The overall incidence of positive histological endometrial findings was greater in group I than in group II (92.9% vs 24.6%, p < 0.0001). Atrophic endometrium or no tissue obtained was more common in group II than in group I (75.3% vs 71.4%, p < 0.0001). Most of the other endometrial pathologies were significantly more common in group I than in group II: endometrial hyperplasia, 35.7% vs 5.6%, p < 0.0001 (in group II, simple endometrial hyperplasia without atypia was found in two patients, complex endometrial hyperplasia without atypia in one, simple endometrial hyperplasia with atypia in one, and complex endometrial hyperplasia with atypia in one; in group I, simple endometrial hyperplasia without atypia was diagnosed in eight patients, complex endometrial hyperplasia without atypia in two, simple endometrial hyperplasia with atypia in one, and complex endometrial hyperplasia with atypia in one); endometrial polyps, 21.5% vs 13.4%, p < 0.0111; and endometrial carcinoma, 7.1% vs 0.9%, p < 0.0001). On hysterectomy specimens we identified atrophic endometrium in five patients (15.2%), endometrial hyperplasia in nine (27.3%), endometrial polyps in 15 (45.5%), and endometrial carcinoma in four (12.0%).

Table 4: Distribution of endometrial histological findings detected in gynaecologically symptomatic (group I) and gynaecologically asymptomatic (group II) postmenopausal breast cancer patients treated with tamoxifen

<table>
<thead>
<tr>
<th>Endometrial histological findings</th>
<th>Group I (n=14)</th>
<th>Group II (n=224)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atrophic and/or &quot;no tissue obtained&quot;</td>
<td>7 (50.0)</td>
<td>169 (75.3)</td>
<td>0.0011</td>
</tr>
<tr>
<td>Proliferative</td>
<td>1 (7.1)</td>
<td>11 (4.8)</td>
<td>NS</td>
</tr>
<tr>
<td>Hyperplasia</td>
<td>5 (35.7)</td>
<td>12 (5.6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Polyps</td>
<td>5 (35.7)</td>
<td>30 (13.4)</td>
<td>&lt;0.0111</td>
</tr>
<tr>
<td>Carcinoma</td>
<td>3 (21.5)</td>
<td>2 (0.9)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Atrophic endometrium or &quot;no tissue obtained&quot;</td>
<td>1 (7.1)</td>
<td>169 (75.3)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Endometrial histological findings overall</td>
<td>13 (92.9)</td>
<td>55 (24.6)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Values are n (%).

Figure 1: Probability of freedom from overall endometrial pathologies with respect to length of tamoxifen treatment in gynaecologically symptomatic and gynaecologically asymptomatic postmenopausal breast cancer patients (n = 224 and n = 14, respectively).

Discussion
There is accumulating evidence of an association between postmenopausal tamoxifen exposure and the development of various endometrial pathologies. Such an association was based on the observation that the incidence of proliferative endometrium, endometrial hyperplasia, endometrial polyps, and endometrial carcinoma were higher among gynaecologically asymptomatic postmenopausal breast cancer patients treated with tamoxifen than in similar untreated patients, although the difference was not statistically significant. Other studies comparing the incidence of endometrial cancer among gynaecologically symptomatic and asymptomatic postmenopausal breast cancer patients treated with tamoxifen with similar untreated controls have shown a significant higher risk of endometrial cancer in the tamoxifen treated patients.

However, most of these reports were retrospective and described pathological findings in patients who were already gynaecologically symptomatic (complaining of postmenopausal vaginal bleeding or blood stained discharge). None compared the incidence of endometrial pathology between gynaecologically asymptomatic and gynaecologically symptomatic postmenopausal breast cancer patients treated with tamoxifen.

In this study we found that the overall incidence of endometrial pathology detected in the gynaecologically symptomatic tamoxifen treated patients (group I) was higher than in comparable gynaecologically asymptomatic patients (group II) (92.9% vs 24.6%, p < 0.0001). The incidence of endometrial hyperplasia, endometrial polyps, and endometrial cancer was also significantly higher in group I than in group II.

The various endometrial pathologies identified appeared considerably later among the gynaecologically asymptomatic patients than in the gynaecologically symptomatic patients (p = 0.0002; fig I). The 92.9% incidence of endometrial pathology detected in the gynaecologically symptomatic tamoxifen patients is higher than that reported overall for all postmenopausal breast cancer patients treated with tamoxifen, or for similar gynaecologically asymptomatic patients.

Although the incidence of overall endometrial pathology of 24.6% detected in the gynaecologically asymptomatic tamoxifen treated...
patients was lower than that found in similar gynaecologically symptomatic patients, it is similar to that reported in our previous studies with smaller numbers of patients, as well as that reported by others.7

There are only three published reports, on relatively small numbers of patients, comparing endometrial histology between these two types of patients.12 14 15

Borenstein et al found no endometrial abnormalities in any of 15 gynaecologically asymptomatic postmenopausal breast cancer patients treated with tamoxifen.11 In seven similar gynaecologically symptomatic patients they identified two endometrial polyps.

Hann et al retrospectively reviewed clinical data of 91 postmenopausal breast cancer patients with tamoxifen treatment.13 Histological evaluation of endometrial specimens was, however, available in only 46 patients. Of these, 20 had postmenopausal bleeding. In the gynaecologically asymptomatic patients there were seven cases of endometrial polyps and two of endometrial hyperplasia. Fourteen of the 20 gynaecologically symptomatic patients had endometrial biopsies which revealed six cases of endometrial polyps, one case of endometrial hyperplasia, and two cases of endometrial carcinoma. Thus the only two cases of endometrial cancer were associated with bleeding. The frequency of endometrial findings reported in these two studies, both in the asymptomatic and in the symptomatic postmenopausal breast cancer patients, is less than we found in our study. Moreover, in contrast to the findings of Hann et al, we also identified endometrial cancer among asymptomatic patients.

Gibson et al reported the results of a retrospective review of endometrial pathology diagnosed by dilatation and curettage performed on 50 gynaecologically symptomatic breast cancer patients on tamoxifen treatment and on 22 similar gynaecologically asymptomatic patients.14 Among asymptomatic tamoxifen users the incidence of endometrial polyps was 15%, endometrial hyperplasia 2%, and endometrial carcinoma 11%, compared with an incidence of 9%, 0%, and 0%, respectively, in the asymptomatic tamoxifen users. All endometrial cancer cases in this study were associated with abnormal vaginal bleeding. We found higher rates of all types of endometrial pathology among both symptomatic and asymptomatic tamoxifen treated patients. Again, in contrast to the results of Gibson et al,14 in our study there were two asymptomatic patients with endometrial cancer. This observation suggests the need to perform transvaginal sonographic follow up in asymptomatic postmenopausal tamoxifen treated patients.

Since the exact incidence of endometrial pathology in the postmenopausal female population is difficult to determine,11 the incidence rates identified in our study among the gynaecologically asymptomatic women, as well as among the entire study patients, is remarkably high.5 Archer et al found distinctly fewer pathological endometrial findings among 801 healthy postmenopausal women.32

In this study we also compared transvaginal sonographic endometrial thickness, demographic characteristics, health habits, and risk factors for endometrial cancer between the two study groups. No difference was found in any of these variables except for a higher parity rate in group II. The relevance of this finding to the significant difference in the incidence of endometrial pathologies between the two study groups is uncertain.

The number of gynaecologically symptomatic patients was much smaller than the number of gynaecologically asymptomatic patients. This is because of the nature of our follow up. We recruited all breast cancer patients for surveillance at the time of the diagnosis of the primary breast cancer was made, and continued to follow them thereafter. When thick endometrium was diagnosed by transvaginal sonography, hysteroscopy and endometrial biopsy were performed. When precancerous lesions were identified the patients were referred for hysterectomy. This follow up management considerably reduced the number of patients with postmenopausal bleeding and probably also the number of patients with endometrial cancer. In fact, only three of the patients who were under our surveillance had this gynaecological symptom, and all had benign endometrial lesions. Moreover, the incidence of endometrial cancer was significantly lower among the gynaecologically asymptomatic than among the gynaecologically symptomatic patients.

It must be emphasised that we might have identified more endometrial polyps after we adopted sonohysterographic evaluation in patients with transvaginal sonographic endometrial thickness of > 8 mm.43

CONCLUSIONS

A high incidence of overall endometrial pathology, including endometrial hyperplasia, endometrial polyps, and endometrial carcinoma, was detected among gynaecologically symptomatic postmenopausal breast cancer patients treated with tamoxifen. The incidence was significantly higher than that found in similar gynaecologically asymptomatic patients. The endometrial pathologies appeared considerably earlier in the symptomatic than in the asymptomatic patients. The incidence of endometrial pathology in the latter group, as well as in the entire study population, is consistent with figures previously reported by ourselves and others, and is higher than rates reported for healthy postmenopausal women.

Except for postmenopausal bleeding or blood stained discharge, no other clinical factor was found to be associated with the different incidence of endometrial pathology found between the two groups.

We thank Mrs Ruth Sheridan for her editorial assistance.

282


Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients.
I Cohen, E Perel, D Flex, R Tepper, M M Altaras, M Cordoba and Y Beyth

*J Clin Pathol* 1999 52: 278-282
doi: 10.1136/jcp.52.4.278

Updated information and services can be found at:
http://jcp.bmj.com/content/52/4/278

*These include:*

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/